Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Olokizumab

Exacerbation of herpes infection

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Baranov AA, et al. MANAGEMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS IN REAL CLINICAL PRACTICE: SWITCHING FROM INTERLEUKIN 6 RECEPTOR INHIBITORS TO INTERLEUKIN 6 INHIBITOR (OLOKIZUMAB). [Russian] Nauchno-Prakticheskaya Revmatologiya 61: 307-319, No. 3, Jan 2023. Available from: URL: 10.47360/1995-4484-2023-307-319 [Russian; summarised from an English abstract] Baranov AA, et al. MANAGEMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS IN REAL CLINICAL PRACTICE: SWITCHING FROM INTERLEUKIN 6 RECEPTOR INHIBITORS TO INTERLEUKIN 6 INHIBITOR (OLOKIZUMAB). [Russian] Nauchno-Prakticheskaya Revmatologiya 61: 307-319, No. 3, Jan 2023. Available from: URL: 10.47360/1995-4484-2023-307-319 [Russian; summarised from an English abstract]
Metadaten
Titel
Olokizumab
Exacerbation of herpes infection
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-56495-4

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Azathioprine